Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TCRT - Alaunos Therapeutics Inc


Previous close
2.67
0   0%

Share volume: 6,176
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.67
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-8.80%
1 Month
-31.12%
3 Months
-75.33%
6 Months
-88.98%
1 Year
-88.43%
2 Year
-99.28%
Key data
Stock price
$2.67
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.11 - $32.85
52 WEEK CHANGE
-$0.88
MARKET CAP 
41.472 M
YIELD 
N/A
SHARES OUTSTANDING 
16.013 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$21,532
AVERAGE 30 VOLUME 
$20,481
Company detail
CEO:
Region: US
Website: ziopharm.com
Employees: 45
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ziopharm oncology, inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. we are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.

Recent news